最新动态
8月17日 - **EyePoint公司（EYPT.O）股价暴跌71%至4.17美元，有望创下有史以来最大单日跌幅，并跌至2025年4月以来的最低点
**这家药物开发商表示，其实验性 眼科药物Duravyu在针对湿性年龄相关性黄斑变性（视力丧失的主要原因之一）患者开展的晚期临床试验中，未能达到主要目标 (link)，该试验旨在与Regeneron公司的重磅眼科药物Eylea进行对比
**该公司补充称， 在排除9名视力丧失与湿性年龄相关性黄斑变性无关的患者后，分析 显示Duravyu的疗效与Eylea相当
** 与Eylea相比，Duravyu将治疗负担降低了42%，即在第56周前可减少约两次注射——EYPT
** 数据显示，截至第56周，54%的患者无需补充注射，79%的患者仅接受零次或一次补充注射
**预计 2026年第四季度将公布 第二项湿性AMD晚期临床研究的数据 ，计划于2027年上半年向FDA提交上市申请
**计入本次交易，该股年初至今累计 跌幅约为77%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.